financetom
Business
financetom
/
Business
/
Capital City Bank Group Insider Sold Shares Worth $328,480, According to a Recent SEC Filing
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Capital City Bank Group Insider Sold Shares Worth $328,480, According to a Recent SEC Filing
Aug 18, 2025 2:07 PM

04:46 PM EDT, 08/18/2025 (MT Newswires) -- Thomas A Barron, Director, Treasurer, on August 14, 2025, sold 8,000 shares in Capital City Bank Group ( CCBG ) for $328,480. Following the Form 4 filing with the SEC, Barron has control over a total of 187,762 common shares of the company, with 143,297 shares held directly and 44,465 controlled indirectly.

SEC Filing:

https://www.sec.gov/Archives/edgar/data/726601/000141588925022179/xslF345X05/form4-08182025_080803.xml

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BBVA Raises Offer for Banco Sabadell by 10% to $20 Billion
BBVA Raises Offer for Banco Sabadell by 10% to $20 Billion
Sep 22, 2025
05:37 AM EDT, 09/22/2025 (MT Newswires) -- Banco Bilbao Vizcaya Argentaria ( BBVA ) said Monday that it has raised its offer to acquire Banco Sabadell by 10% to 17 billion euros ($20 billion). Under the new bid, BBVA will offer one share for every 4.8376 Banco Sabadell shares, valuing Banco Sabadell shares at 3.39 euros apiece. The new offer...
Sanofi Says FDA Extends Target Action Date of Tolebrutinib Application Review by 3 Months
Sanofi Says FDA Extends Target Action Date of Tolebrutinib Application Review by 3 Months
Sep 22, 2025
05:00 AM EDT, 09/22/2025 (MT Newswires) -- Sanofi ( SNY ) said Monday the US Food and Drug Administration has extended the target action date of its review of the new drug application of tolebrutinib to treat non-relapsing, secondary progressive multiple sclerosis by three months. The FDA determined that the additional information constituted a major amendment to the application, based...
Form 8.3 - Deliveroo PLC
Form 8.3 - Deliveroo PLC
Sep 22, 2025
LONDON--(BUSINESS WIRE)--   FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of...
Alvotech, Partner Say European Medicines Agency Recommends Gobivaz Marketing Approval
Alvotech, Partner Say European Medicines Agency Recommends Gobivaz Marketing Approval
Sep 22, 2025
05:38 AM EDT, 09/22/2025 (MT Newswires) -- Alvotech ( ALVO ) and partner Advanz Pharma said Monday the European Medicines Agency's Committee for Medicinal Products for Human use adopted a positive opinion recommending approval for Gobivaz, the proposed biosimilar to Simponi, a biologic used to treat several chronic inflammatory diseases. Gobivaz continues to be under EMA regulatory review, with a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved